A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.
Hughes WT, Feldman S, Hermann HW. Safety of Megadosage Haloprogin. Arch Dermatol. 1974;110(6):926–928. doi:10.1001/archderm.1974.01630120072018
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.